

Krebs Biochemicals & Industries Limited

8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034

CIN : L24110TG1991PLCO13511



9th November, 2015

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

Sub: Submission of Unaudited Financial Results for the quarter ended 30th September, 2015.


Ref: Clause 41 of the Listing Agreement

We refer to the above mentioned subject, we herewith submit the Exchange the unaudited financial results and the Limited Review Report for the quarter and half year ended 30th September, 2015 as required under Clause 41 of the Listing Agreement.

This is for the information and records of the Exchange, Please.

Thanking You,
Yours Faithfully,

For Krebs Biochemicals & Industries Limited


Haritha Varanasi
Company Secretary



Encl. as above.

Tel : 0091-(0) 40-66037777 Fax : 0091-(0) 40-66037755

E-mail : krebs@krebsbiochem.com, marketing@krebsbiochem.com URL : www.krebsbiochem.com

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN: L24110TG1991PLC013511

Regd. Office: Plot No:38, 8-2-577/B, Maas Heights, Road No:2, Banjara Hills, Hyderabad -500034

STAND ALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2015

(Rs. In lacs)

Particulars	Quarter Ended			Half Year Ended		Previous Year Ended (6 Months)
	30.09.2015 (Unaudited)	30.06.2015 (Unaudited)	30.09.2014 (Audited)	30.09.2015 (Unaudited)	30.09.2014 (Audited)	31.03.2015 (Audited)
PART - 1						
1 Income from Operations						
a) Net Sales / Income from Operations (Net of Excise Duty)	-	15.85	-	15.85	-	-
b) Other Operating Income	34.21	-	-	34.21	-	-
Total Income from operations (net)	34.21	15.85	-	50.06	-	-
2 Expenses						
a. Cost of Material Consumed	166.84	17.28	-	184.12	-	-
b. Changes in inventories of finished goods, work-in-progress and stock -in-trade	(241.64)	(5.19)	-	(246.83)	-	-
c. Employee benefits expense	109.08	138.53	(305.59)	247.61	(295.32)	185.67
d. Depreciation and Amortisation expense	95.54	95.54	-	191.08	-	187.13
e. Other Manufacturing Expenses	160.72	113.64	0.05	274.36	0.24	90.76
f. Other Expenses	99.17	62.90	30.87	162.07	87.48	213.82
Total Expenses	389.71	422.70	(274.67)	812.41	(207.60)	677.38
3 Profit / (Loss) from Operations before other income, finance costs and exceptional items (1 - 2)	(355.50)	(406.85)	274.67	(762.35)	207.60	(677.38)
4 Other Income	60.76	0.75	(317.27)	61.51	1.80	1.12
5 Profit / (Loss) from ordinary activities before finance costs (3 ± 4)	(294.74)	(406.10)	(42.60)	(700.84)	209.40	(676.26)
6 Finance Costs	4.07	0.20	0.08	4.27	0.79	402.85
7 Profit / (Loss) from Ordinary Activities before tax (5 ± 6)	(298.81)	(406.30)	(42.68)	(705.11)	208.61	(1,079.11)
8 Exceptional Items:						
a) Debit balances written off	-	-	-	-	-	(692.16)
b) Waiver of Principal of Bank Loans & Others	-	-	-	-	-	3,625.17
c) Depletion in Value of Inventory	(126.93)	-	-	(126.93)	-	(2,637.91)
d) Amounts Written Back	18.07	52.03	-	70.10	-	-
e) Profit on Sale of Food Division's Immovables	-	59.12	-	59.12	-	-
f) Excess Provision of Earlier Period Written Back	-	-	15.55	-	15.55	-
9 Net Profit / (Loss) for the period (7 ± 8)	(407.67)	(295.15)	(27.13)	(702.82)	224.16	(784.01)
10 Tax Expense	-	-	(39.99)	-	(39.99)	-
11 Net Profit / (Loss) from ordinary activities after Tax (9 ± 10)	(407.67)	(295.15)	(67.12)	(702.82)	184.17	(784.01)
12 Paid-up Equity Share Capital (Face Value Rs. 10/- each)	1241.43	1,241.43	951.43	1241.43	951.43	951.43
13 Earning Per Share ((not annualised for the quarter)						
(a) Basic	(3.28)	(2.38)	(0.71)	(5.66)	1.94	(8.24)
(b) Diluted	(3.28)	(2.38)	(0.71)	(5.66)	1.94	(8.24)
PART - 2						
A PARTICULARS OF SHAREHOLDING						
1 Public Share Holding						
- Number of Shares	55,29,646	55,29,646	49,16,146	55,29,646	49,16,146	67,16,146
- Percentage of Shareholding	44.54%	44.54%	51.67%	44.54%	51.67%	70.59%
2 Promoter and Promoter Group Shareholding						
a) Pledged / Encumbered						
- Number of Shares	24,00,000	22,08,400	42,61,724	24,00,000	42,61,724	22,08,400
- Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	34.86%	32.08%	92.68%	34.86%	92.68%	78.92%
- Percentage of Shares (as a % of total share capital of the Company)	19.33%	17.79%	44.79%	19.33%	44.79%	23.21%
b) Non - Pledged / Encumbered						
- Number of Shares	44,84,640	46,76,240	3,36,416	44,84,640	3,36,416	5,89,740
- Percentage of Shares (as a % of total shareholding of promoter and promoters group)	65.14%	67.92%	7.32%	65.14%	7.32%	21.08%
- Percentage of Shares (as a % of total share capital of the Company)	36.13%	37.67%	3.53%	36.13%	3.53%	6.20%

PARTICULARS

B INVESTOR COMPLAINTS			
1 PENDING AT THE BEGINNING OF THE QUARTER		0	
2 RECEIVED DURING THE QUARTER		4	
3 DISPOSED OFF DURING THE QUARTER		4	
4 REMAINING UNRESOLVED AT THE END OF THE QUARTER		0	

- The above results have been reviewed by the Audit Committee at its meeting held on 9th Nov, 2015 and approved by the Board of Directors of the Company at its meeting held on 9th Nov, 2015.
- The Above results are subjected to limited review by Company's Statutory Auditors.
- The Company is operating in one segment only hence no segment results have been disclosed
- Figures have been regrouped, rearranged wherever necessary.
- The company has allotted 6.50 lacs equity shares and 6.80 lacs convertible warrants on 03.10.2015 and the same was approved by share holders on 10.10.2015

Place : Hyderabad

Date : 09-11-2015

Avinash R
Managing Director

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN: L24110TG1991PLC013511

Regd. Office: Plot No:38, 8-2-577/B, Maas Heights, Road No:2, Banjara Hills, Hyderabad -500034

STAND ALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30th SEPTEMBER 2015

Statement of Assets and Liabilities	Rs in Lakhs	
	As at 30.09.2015 Un Audited	As at 31.03.2015 Audited
I. <u>EQUITY AND LIABILITIES</u>		
(1) Shareholder's funds:		
(a) Share capital	1,241.43	951.43
(c) Reserves and surplus	(834.74)	(1,407.92)
(b) Money Received against Share Warrants	367.20	367.20
Sub Total - Share holders Funds	773.89	(89.29)
(2) Share application Money Pending Allotment	351.00	1,917.00
(3) Non-current liabilities		
(a) Long-term borrowings	6,564.72	5,708.71
(b) Long-term provisions	204.65	206.30
Sub Total - Non Current Liabilities	6,769.37	5,915.01
(4) Current liabilities		
(a) Short-term borrowings	-	-
(b) Trade payables	1,376.08	1,654.27
(c) Other current liabilities	1,245.48	1,261.43
(d) Short-term provisions	185.44	185.50
Sub Total - Current Liabilities	2,807.00	3,101.19
TOTAL - EQUITY AND LIABILITIES	10,701.26	10,843.91
II. <u>ASSETS</u>		
(1) Non-current assets		
(a) Fixed assets		
(i) Tangible assets	5,427.13	5,097.94
(ii) Intangible assets under development	488.01	746.28
(b) Deferred Tax asset (Net)	131.30	131.30
(c) Long-term loans and advances	1,210.75	1,211.82
(d) Other Non-current assets	2,173.83	2,169.80
Sub Total - Non Current Assets	9,431.02	9,357.15
(2) Current assets		
(a) Inventories	635.44	545.30
(b) Trade receivables	10.44	37.28
(c) Cash and cash equivalents	34.13	630.94
(d) Short-term loans and advances	590.23	273.25
Sub Total - Current Assets	1,270.24	1,486.78
TOTAL - ASSETS	10,701.26	10,843.92

Place : Hyderabad

Date : 09-11-2015


 Avinash Rayi
 Managing Director
 DIN: 01616152



PAVULURI & Co.

CHARTERED ACCOUNTANTS

105, 1st Block, 1st Floor, Divya Shakti Complex,
Ameerpet, Hyderabad - 500 016.

Ph : 040 - 2373 1837, 4025 8691

Fax : 040 - 2374 8729

Email : pavuluriandco@gmail.com

pavuluriandco@hotmail.com

Review Report to the Board of Directors of Krebs Biochemicals & Industries Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Krebs Biochemicals & Industries Limited** (" the company") for the quarter **30th September, 2015** except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results for the Quarter ended 30th September 2015 prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date : 09.11.2015

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S


(CA. P A RAMAIAH)
PARTNER
M.No: F-203300

